REGENXBIO Inc.
Price Action
Technical Summary
CONSOLIDATINGREGENXBIO Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 28), showing significant lag compared to the market leaders. Earnings contraction of 3% provides fundamental context to the price action. Investors should exercise caution due to high volatility (81% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.20 | +13.32% | ABOVE |
| 50 SMA | $8.90 | +17.14% | ABOVE |
| 100 SMA | $10.61 | -1.79% | BELOW |
| 150 SMA | $11.10 | -6.13% | BELOW |
| 200 SMA | $10.56 | -1.32% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RGNX in an uptrend right now?
RGNX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is RGNX overbought or oversold?
RGNX's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is RGNX outperforming the market?
RGNX has a Relative Strength (RS) Rating of 28 out of 99. RGNX is currently lagging the broader market.
Where is RGNX in its 52-week range?
RGNX is trading at $10.42, which is 64% of its 52-week high ($16.19) and 38% above its 52-week low ($6.89).
How volatile is RGNX?
RGNX has a Beta of 2.59 and 52-week volatility of 81%. It's more volatile than the S&P 500 - expect bigger swings.